GlassScriptPhysician profile
David M Burke
NPI 1316970254
$4,142.66
in general payments reported to CMS, 2019-2025
35 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $390 · 2021: $566 · 2022: $365 · 2023: $261 · 2024: $668 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,957 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,956.92 |
| Education | $143.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,086.57 | 2021-2025 | Qulipta, Ubrelvy |
| Biogen, INC. | $626.63 | 2019-2025 | Tecfidera, Skyclarys, Tysabri |
| Novartis Pharmaceuticals Corporation | $302.57 | 2019-2025 | |
| Emd Serono, INC. | $235.31 | 2020-2025 | Mavenclad |
| Lundbeck LLC | $191.83 | 2025 | Vyepti |
| Pfizer INC. | $136.85 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $117.70 | 2019-2021 | |
| Amgen INC. | $117.46 | 2019-2024 | Uplizna |
| Neurocrine Biosciences, INC. | $100.57 | 2020-2024 | Ingrezza |
| Acadia Pharmaceuticals INC | $89.85 | 2024-2025 | Nuplazid |
| Genzyme Corporation | $87.52 | 2019-2025 | |
| Genentech USA, INC. | $83.95 | 2019-2024 | Ocrevus Zunovo |
| Lilly USA, LLC | $83.16 | 2019-2025 | Kisunla |
| Allergan, INC. | $82.66 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $82.37 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $75.12 | 2019-2022 | |
| Ge Healthcare | $60.84 | 2019 | |
| Eisai INC. | $59.46 | 2023-2024 | |
| Tg Therapeutics, INC. | $53.49 | 2023-2025 | |
| Acorda Therapeutics, INC | $50.74 | 2019-2021 | |
| Argenx US, INC. | $44.68 | 2024-2025 | Vyvgart Hytrulo |
| Grifols USA, LLC | $43.78 | 2020 | |
| Greenwich Biosciences, INC. | $39.99 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $37.48 | 2025 | Fanapt |
| Sk Life Science, INC. | $35.58 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $30.91 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.00 | 2022 | |
| Csl Behring | $29.87 | 2019-2025 | Hizentra |
| Livanova USA, INC. | $23.20 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.52 | 2025 | Rexulti |
| Life Molecular Imaging LTD | $20.48 | 2024 | Neuraceq |
| Sumitomo Pharma America, INC. | $19.22 | 2024 | Gemtesa |
| Tanabe Pharma America, INC. | $15.71 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.46 | 2020 | |
| Impel Pharmaceuticals INC. | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.